![]() Medications that affect gastrointestinal and urinary pH may affect serum concentrations of amphetamine. 5 Because amphetamines are renally excreted, dosages should be adjusted in patients with renal impairment.ĭ rug interactions. ![]() Amphetamines are partially metabolized through cytochrome 450 (CYP) 2D6-dependent mechanisms, and thus in CYP2D6 poor metabolizers medication exposure may be increased, while decreased exposure may occur in ultra-rapid metabolizers however, there are no guidelines from the Clinical Pharmacogenetics Implementation Consortium regarding alternate dosing strategies for patients based on CYP2D6 genotype or activity phenotype. Half-life is 10 to 11 hours for d-amphetamine and 10 to 13 hours for l -amphetamine and does not statistically differ between pediatric and adult studies. test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. Backhaus J, Junghanns K, Broocks A, et al. A Long-term, open-label, safety study of triple-bead mixed amphetamine salts (SHP465) in adults with ADHD. Presented at: 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry OctoBoston, MA.ĩ. Clinical evaluation of triple-bead mixed amphetamine salts in adult ADHD. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. Connolly SD, Bernstein GA Work Group on Quality Issues. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. Walkup JT, Albano AM, Piacentini J, et al. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Hoffman JM, Dunnenberger HM, Kevin Hicks J, et al. Amphetamine, past and present-a pharmacological and clinical perspective. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. ![]() Castells X, Ramos-Quiroga J, Bosch R, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Picard reports no financial relationship with any company whose products are mentioned in this article or with manufacturers of competing products.ġ. He has not been involved in any advisory role, clinical trials, or promotional speaking for the compound featured in this article. Strawn’s work with Shire involved guanfacine, extended-release, for anxiety disorders in youth. Strawn has received research support from Eli Lilly, Edgemont, Shire, Forest Research Laboratories, Lundbeck, the National Institute of Mental Health, and Neuronetics has received royalties from Springer for the publication of 2 texts and has received material support from Assurex Health. Winkle College of Pharmacy, Cincinnati, Ohio.ĭr. Picard is Clinical Pharmacist, Mercy Health Partners, Cincinnati, Ohio, and Adjunct Assistant Professor of Pharmacy Practice, University of Cincinnati, James L. Strawn is Associate Professor of Psychiatry, University of Cincinnati, College of Medicine, Cincinnati, Ohio, and Child and Adolescent Section Editor of Current Psychiatry.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |